The Phase 3 study LITESPARK 011, studying belzutifan plus lenvatinib versus cabozantinib in advanced RCC after anti-PD-1/PD-L1 therapy, has completed accrual and results are awaited. Here, CD274 is linked to renal cell carcinoma.